RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
FUTURE ONCOLOGY (LONDON, ENGLAND)
Collezione AOU San Luigi di Orbassano

Items : 19

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary. in Future oncology (London, England) / Future Oncol. 2025 Mar 24:1-12. doi: 10.1080/14796694.2025.2474789.

2025
AOU San Luigi di Orbassano

de Langen AJ; Johnson ML; Mazieres J; Dingemans AC; Mountzios G; Pless M; Wolf J; Schuler M; Lena H; Skoulidis F; Yoneshima Y; Kim SW; Linardou H; Novello S; van der Wekken AJ; Chen Y; Peters S; Felip E; Solomon BJ; Ramalingam SS; Dooms C; Lindsay CR; Ferreira CG; Blais N; Obiozor CC; Wang Y; Mehta B; Varrieur T; Ngarmchamnanrith G; et alii...

HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI. in Future oncology (London, England) / Future Oncol. 2024 May;20(15):969-980. doi: 10.2217/fon-2023-0602. Epub 2023 Dec 14.

2024
AOU San Luigi di Orbassano

Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA; Mok T; Jänne PA; Nishio M; Novello S; Reck M; Steuer C; Wu YL; Fougeray R; Fan PD; Meng J; Sternberg DW; Esker S; Yu HA;

Extension of lymph node dissection in the surgical treatment of esophageal and gastroesophageal junction cancer: seven questions and answers. in Future oncology (London, England) / Future Oncol. 2023 Feb;19(4):327-339. doi: 10.2217/fon-2021-0545. Epub 2023 Mar 21.

2023
AOU San Luigi di Orbassano

Vagliasindi A; Franco FD; Degiuli M; Papis D; Migliore M;

A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. in Future oncology (London, England) / Future Oncol. 2021 Oct;17(30):3987-3994. doi: 10.2217/fon-2020-1298. Epub 2021 Jul 19.

2021
AOU San Luigi di Orbassano

Ferro M; Lucarelli G; de Cobelli O; Dolce P; Terracciano D; Musi G; Porreca A; Busetto GM; Del Giudice F; Soria F; Gontero P; Cantiello F; Damiano R; Crocerossa F; Abu Farhan AR; Autorino R; Vartolomei MD; Marchioni M; Mari A; Minervini A; Longo N; Celentano G; Chiancone F; Perdonà S; Del Prete P; Ditonno P; Battaglia M; Zamboni S; Antonelli A; et alii...

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):763-773. doi: 10.2217/fon-2020-0935. Epub 2020 Nov 5.

2021
AOU San Luigi di Orbassano

Novello S; F Loong HH; Lin BK; Lin AB; Sashegyi A; Soldatenkova V; Davis HM; Elamin Y; Wolf J; Park K; Drilon A; Zhou CC; Solomon BJ; Arriola E; Pérol M; Goto K; Santini FC;

Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):807-815. doi: 10.2217/fon-2020-0391. Epub 2021 Jan 29.

2021
ASL Asti
AOU San Luigi di Orbassano

Salgarello M; Borsatti E; Pignata S; Zichi C; Filice A; Murabito A; Biasco E; Fanti S; Palermo A; Alongi P; Alongi F; Bortolus R; Facchini G; Baldari S; Tucci M; Pinto C; Costa RP; Sbrana A; Monari F; Caffo O; Frantellizzi V; Spada M; Cortesi E; Vincentis G;

What does the future hold for the Lung Cancer Ambition Alliance project: an interview with Giorgio Scagliotti. in Future oncology (London, England) / Future Oncol. 2020 Mar;16(7):221-223. doi: 10.2217/fon-2019-0738. Epub 2020 Feb 5.

2020
AOU San Luigi di Orbassano

Scagliotti G;

Nilotinib in the treatment of chronic myeloid leukemia. in Future oncology (London, England) / Future Oncol. 2019 Mar;15(9):953-965. doi: 10.2217/fon-2018-0468. Epub 2018 Dec 14.

2019
AOU San Luigi di Orbassano

Sacha T; Saglio G;

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review. in Future oncology (London, England) / Future Oncol. 2019 Mar;15(9):989-994. doi: 10.2217/fon-2018-0469. Epub 2019 Jan 25.

2019
AOU San Luigi di Orbassano

Abbate MI; Cortinovis DL; Tiseo M; Vavalà T; Cerea G; Toschi L; Canova S; Colonese F; Bidoli P;

Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy. in Future oncology (London, England) / Future Oncol. 2019 Jul;15(21):2543-2553. doi: 10.2217/fon-2018-0772. Epub 2019 Jun 26.

2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Locati LD; Di Giannantonio V; Sbrana A; Musettini G; Sonetto C; Bironzo P; Botta L; Bossi P; Di Maio M; Antonuzzo A;

Long-term disease control and high clinical benefit in a patient with advanced thyroid cancer treated with lenvatinib. in Future oncology (London, England) / Future Oncol. 2019 Aug;15(24s):3-6. doi: 10.2217/fon-2019-0092. Epub 2019 Aug 6.

2019
AOU San Luigi di Orbassano

Muratori L; Sperone P; Scagliotti GV;

Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2019 Apr;15(10):1115-1123. doi: 10.2217/fon-2018-0715. Epub 2019 Mar 19.

2019
AOU San Luigi di Orbassano

Caffo O; Facchini G; Biasco E; Ferraù F; Morelli F; Donini M; Buttigliero C; Calvani N; Guida A; Chiuri VE; Basso U; Mucciarini C; Conteduca V; Rossetti S; Veccia A; Maines F; Kinspergher S; De Giorgi U;

Thymidine phosphorylase: the unforeseen driver in colorectal cancer treatment? in Future oncology (London, England) / Future Oncol. 2018 May;14(12):1223-1231. doi: 10.2217/fon-2017-0627. Epub 2018 Apr 27.

2018
AOU San Luigi di Orbassano

Tampellini M; Bironzo P; Di Maio M; Scagliotti GV;

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. in Future oncology (London, England) / Future Oncol. 2018 Feb;14(4):353-361. doi: 10.2217/fon-2017-0441. Epub 2017 Nov 14.

2018
AOU San Luigi di Orbassano

Metro G; Passaro A; Lo Russo G; Bonanno L; Giusti R; Gregorc V; Capelletto E; Martelli O; Cecere FL; Giannarelli D; Luciani A; Bearz A; Tuzi A; Scotti V; Tonini G; Galetta D; Carta A; Soto Parra H; Rebonato A; Morabito A; Chiari R; Metro G; Passaro A; Lo Russo G; Bonanno L; Giusti R; Gregorc V; Capelletto E; Martelli O; et alii...

Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives. in Future oncology (London, England) / Future Oncol. 2018 Dec;14(29):3073-3083. doi: 10.2217/fon-2018-0287. Epub 2018 Aug 15.

2018
AOU San Luigi di Orbassano

Hiser WM; Sangiorgio V; Bollito E; Esnakula A; Feely M; Falzarano SM;

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18.

2016
AOU San Luigi di Orbassano

Veccia A; Caffo O; De Giorgi U; Di Lorenzo G; Ortega C; Scognamiglio F; Aieta M; Facchini G; Mansueto G; Mattioli R; Procopio G; Zagonel V; D'Angelo A; Spizzo G; Bortolus R; Donini M; Lo Re G; Massari F; Vicario G; Zucali PA; Alesini D; Bonetti A; Mucciarini C; Nicodemo M; Berruti A; Fratino L; Lodde M; Messina C; Perin A; et alii...

Metastatic castration-resistant prostate cancer: time for innovation. in Future oncology (London, England) / Future Oncol. 2015;11(1):91-106. doi: 10.2217/fon.14.145.

2015
AOU San Luigi di Orbassano

Tucci M; Scagliotti GV; Vignani F;

First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. in Future oncology (London, England) / Future Oncol. 2014 May;10(6):1081-93. doi: 10.2217/fon.13.247.

2014
AOU San Luigi di Orbassano

Capelletto E; Novello S; Scagliotti GV;

Lung cancer and women. in Future oncology (London, England) / Future Oncol. 2008 Oct;4(5):705-16. doi: 10.2217/14796694.4.5.705.

2008
AOU San Luigi di Orbassano

Novello S; Vavalà T;